Lamotrigine 10 MG/ML Oral Suspension — RxCUI 2724462
RxNorm drug concept · Semantic clinical drug
RxCUI 2724462
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2724462
Official nameLamotrigine 10 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Lamotrigine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats epilepsy, helping control certain seizure types. Some forms, like tablets, chewables and orally disintegrating tablets, are also used to delay mood episodes in bipolar I...
- Lamotrigine can cause serious, even life-threatening skin reactions, mostly in the first 2 to 8 weeks. We can't tell which rashes are dangerous, so call your doctor right away abou...
- Take it by mouth exactly as prescribed, increasing slowly as planned. Skipping ahead raises rash risk. Extended-release tablets are once daily and must be swallowed whole. Food doe...
- Please don't stop on your own. Stopping suddenly can trigger withdrawal seizures. Your doctor will taper you off over at least 2 weeks.
🕸️ Concept Web — How Lamotrigine 10 MG/ML Oral Suspension Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Lamotrigine 10 MG/ML Oral Suspension
RxCUI 2724462 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Lamotrigine
28439IN
-
Lamotrigine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Subvenite
2001501BN
-
Subvenite
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Lamotrigine Oral Suspension
2724461SCDF -
Lamotrigine Oral Liquid Product
2697773SCDG -
Lamotrigine Oral Product
1162535SCDG -
Lamotrigine Oral Suspension [Subvenite]
2724465SBDF -
Subvenite Oral Liquid Product
2724464SBDG -
Subvenite Oral Product
2001504SBDG -
Oral Suspension
316969DF -
Oral Liquid Product
1151137DFG - +1 more in this family
-
Lamotrigine Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Lamotrigine 10 MG/ML
2724460SCDC -
Lamotrigine 10 MG/ML Oral Suspension [Subvenite]
2724466SBD -
Lamotrigine 10 MG/ML [Subvenite]
2724463SBDC
-
Lamotrigine 10 MG/ML
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Lamotrigine 10 MG/ML
SCDC · 2724460 -
Lamotrigine Oral Suspension
SCDF · 2724461 -
Lamotrigine Oral Liquid Product
SCDG · 2697773 -
Lamotrigine Oral Product
SCDG · 1162535
Brand-Name Concepts
-
Lamotrigine 10 MG/ML Oral Suspension [Subvenite]
SBD · 2724466 -
Lamotrigine 10 MG/ML [Subvenite]
SBDC · 2724463 -
Lamotrigine Oral Suspension [Subvenite]
SBDF · 2724465 -
Subvenite Oral Liquid Product
SBDG · 2724464 -
Subvenite Oral Product
SBDG · 2001504 -
Subvenite
BN · 2001501
📦 FDA Products & Package NDCs
1 product · 2 package NDCs
2 package NDCs map to RxCUI 2724462 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 69102-0418-01 | 1 BOTTLE in 1 PACKAGE (69102-418-01) / 240 mL in 1 BOTTLE | SUBVENITE | OWP Pharmaceuticals, Inc. | 2025-10-01 |
| 69102-0418-02 | 2 BOTTLE in 1 PACKAGE (69102-418-02) / 240 mL in 1 BOTTLE | SUBVENITE | OWP Pharmaceuticals, Inc. | 2025-10-01 |
Observed labelers:
OWP Pharmaceuticals, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.